{
  "meta": {
    "data_length": 1,
    "message": "Indication id ind:ema.caprelsa:0 retrieved successfully",
    "request_url": "http://api.moalmanac.org/indications?indication_id=ind%3Aema.caprelsa%3A0",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.003814,
    "timestamp_received": "2026-04-24T03:09:15.483986+00:00Z",
    "timestamp_returned": "2026-04-24T03:09:15.487800+00:00Z",
    "trace_id": "ebcb08b5-728e-48b8-8bc7-d293dd569d05"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://dev.moalmanac.org",
    "last_updated": "2026-04-09"
  },
  "data": [
    {
      "id": "ind:ema.caprelsa:0",
      "indication": "Caprelsa is indicated for the treatment of aggressive and symptomatic Rearranged during Transfection (RET) mutant medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. Caprelsa is indicated in adults, children and adolescents aged 5 years and older.",
      "initial_approval_date": "2023-03-09",
      "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/caprelsa-h-c-2315-ii-0043-epar-assessment-report-variation_en.pdf",
      "description": "The European Medicines Agency (EMA) has authorized vandetanib for the treatment of aggressive and symptomatic Rearranged during Transfection (RET) mutant medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. Vandetanib is indicated in adults, children, and adolescents aged 5 years and older.",
      "raw_biomarkers": null,
      "raw_cancer_type": "Medullary thyroid cancer",
      "raw_therapeutics": "Caprelsa (vandetanib)",
      "icd10": null,
      "regimen_code": null,
      "reimbursement_category": null,
      "reimbursement_date": null,
      "reimbursement_details": null,
      "date_regular_approval": null,
      "date_accelerated_approval": null,
      "document": {
        "id": "doc:ema.caprelsa",
        "type": "Document",
        "documentType": "Regulatory approval",
        "name": "Caprelsa (vandetanib) [product information]. EMA.",
        "title": null,
        "aliases": [],
        "description": "Sanofi B.V. Caprelsa (vandetanib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/caprelsa-epar-product-information_en.pdf. Revised August 2023. Accessed March 6, 2024.",
        "urls": [
          "https://www.ema.europa.eu/en/medicines/human/EPAR/caprelsa",
          "https://www.ema.europa.eu/en/documents/product-information/caprelsa-epar-product-information_en.pdf"
        ],
        "doi": null,
        "pmid": null,
        "extensions": [
          {
            "name": "agent",
            "value": {
              "id": "ema",
              "type": "Agent",
              "agentType": "organization",
              "name": "European Medicines Agency",
              "description": "Regulatory agency that approves medicines for use in the European Union.",
              "extensions": [
                {
                  "name": "last_updated",
                  "value": "2025-10-01",
                  "description": ""
                },
                {
                  "name": "url",
                  "value": "https://www.ema.europa.eu/en/medicines",
                  "description": ""
                }
              ]
            },
            "description": "The organization that published this document."
          },
          {
            "name": "company",
            "value": "Sanofi B.V.",
            "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
          },
          {
            "name": "drug_name_brand",
            "value": "Caprelsa",
            "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
          },
          {
            "name": "drug_name_generic",
            "value": "vandetanib",
            "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
          },
          {
            "name": "first_publication_date",
            "value": "2012-03-02",
            "description": "The publication date for the initial version of this document."
          },
          {
            "name": "identification_number",
            "value": null,
            "description": "Identification number used by the publishing organization."
          },
          {
            "name": "publication_date",
            "value": "2023-08-16",
            "description": "The publication date for the document."
          },
          {
            "name": "status",
            "value": "Active",
            "description": "Whether this document is Active or Deprecated within moalmanac-db."
          }
        ]
      }
    }
  ]
}